The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP. AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu.

LOS ANGELES, April 28, 2025--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical ...

The deadline for early registration and hotel reservations is April 23, 2025, at 11:59 PM ET. Below you will find registration rates and details, hotel information, and links to book your hotel and ...

Now we would like to begin Daiichi Sankyo's Financial Results Conference ... Okay, in terms of ASCO 2025, next slide, I want to alert all of you to the fact that we want to hold an Investor ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in patients with HER2-positive ...

The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any ... Honoraria: Roche, AstraZeneca, MSD ...

Determining Residents' Concerns About Staying Up to Date: Turkish Society for Radiation Oncology-Young Radiation Oncologists' Cross-Sectional National Survey (TROD/GROG 007) These findings highlight ...

Debt-ridden Shivinder Mohan Singh faces over ₹3,500 crore recovery in an arbitration from the Japanese drug maker Daiichi Sankyo. In his plea, Singh has submitted that his liabilities now far exceed ...